Google Search

Search

Already a Member ?

Best Business Opportunities in Turkey, Middle East- Identification and Selection of right Project, Thrust areas for Investment, Industry Startup and Entrepreneurship Projects

Why should start a Business in Turkey?

Turkey is Europe's sixth-largest economy in terms of economic growth, and its investment and business sectors are rapidly developing. Turkey attracts foreign investments because of its talented labour, low beginning costs, and strategic location. You can invest in construction, automobiles and metals, information technology, the environment, energy, agriculture, textiles, finance, and tourism, to name a few.

It is vital to identify the places in which to invest before starting a business in Turkey. The four best provinces to establish a business in are as follows: Textiles, cement, paper, chemical products, processed food, and a variety of other items can be purchased. The Marmara Region produces 70% of Turkey's sunflowers and 30% of its grain, oil, and wine.

The Marmara Region is one of Turkey's most desirable places to start a business because of its strengths in manufacturing, international trade, and tourism. Turkey received $3.93 billion in foreign direct investment last year, with the service sector receiving around 3.2 million dollars. As a result of many foreigners deciding to do business in Turkey, there has been an increase in direct foreign investment. The most foreign direct investment is attracted by most industries, such as banking, manufacturing, and energy.

 

What are the Natural Resources in Turkey?

Turkey's natural resources include iron ore, copper, coal, chromium, antimony, mercury, gold, celestite (strontium), emery, barite, borate feldspar, pyrites, clay, limestone, magnesite, marble, perlite, and pumice. The country plays an important role in the transportation of crude oil and natural gas. Minerals and pumice from around the world It produced chromite, feldspar, barite, bentonite, kaolin, magnesite, and perlite in the same year. Turkey's gold reserves are estimated to be over 23 million ounces. There are four active gold mines in the area right now, with four more in the planning phases. According to current reports, Eldorado Gold Corp's Usak - Kisladag mine is the country's largest gold producer, with a 12 million ounce reserve.

  • Natural gas is a form of fuel that is utilised in a variety of applications. Turkey consumes a lot of natural gas, the majority of which is imported. However, it has the potential to boost domestic output, particularly through shale gas. Turkey produced 48.6 billion cubic metres of natural gas in 2014, up from 0.5 billion cubic metres the previous year.
  • Turkey produces more coal than oil and gas, with the majority of it going to power plants. Turkey really produced approximately 1.5 million tonnes of hard coal, accounting for roughly 40% of the country's entire energy output.
  • Turkey's iron ore resources are estimated to be 83 million tonnes and are dispersed over the country, with the most of it concentrated in Anatolia, Erzincan, Malatya, and Sivas. Production levels have stayed essentially consistent over time due to a lack of reserves. The Avnik mine, 452 miles east of Ankara in Bingol Province, contains one of Turkey's largest iron ore reserves. There are 44 million tonnes of iron metal in the reserve, and 105 million tonnes of ore grading 42 percent iron are projected to be available.
  • In some locations of Turkey, gold is mined on a small basis. Turkey was a notable gold producer in 2012, with a total of 29.5 tonnes of gold mined around the country. The Kşlada mine, located in Uşak Province and owned and operated by the Canadian Eldorado Gold Company, is the country's largest gold mine. The öpler mine is also one of Turkey's and the world's largest gold mines.

 

What are the Business Opportunities in Turkey?

Turkey's strategic location between Europe and the Middle East makes it a vital commercial and business hub for both Europe and the Middle East. As a result, you have a good possibility of developing and expanding your business idea in Turkey.

1. You will locate hardworking youth labour for your company ideas in Turkey. When it comes to starting a business, this is a major advantage for young companies. Turkey is a natural stone warehouse and one of the top exporters in the world. In addition, the country ranks fourth in the world for marble production. As a result, natural stone mining is a lucrative and promising business venture for you. Marble, limestone, basalt, tuff, granite, travertine, onyx, and slate are among natural stones that can be mined.

2. Turkey's automobile industry is vast and growing. As a result, selling automobile components could be a profitable company for you. Create a facility that will manufacture a wide range of vehicle spare parts.

3. Turkey's textile industry is booming and garnering international acclaim. As a result, you might want to explore beginning a clothing export company. You can start your own label and sell your products both domestically and abroad if you know how to design clothes and have a good sense of style.

4. It requires little money to get started, making it simple to get started. You can sell Turkish delicacies as well as popular fast food favourites like burgers and French fries. Keep in mind that the food should be of the highest quality and be as fresh as possible. Packaged food delivery is a very profitable company in Turkey because of the large number of individuals that go to work.

5. As a result, both local and tourist customers will flock to your restaurant. Serve authentic cuisine and make an investment in your restaurant's environment and serving ware. Keep in mind that your restaurant's cleanliness and the quality of your personnel are crucial.

 

Business-Friendly Policies and Government Initiatives;

Turkey is one of those countries where launching a business is quite straightforward. If you still have doubts, there are a slew of legislation that make life easier for entrepreneurs, as well as a slew of organisations and other services that aid in the success of new firms. In recent years, the Turkish government has taken a number of steps to improve the business climate and make it easier for entrepreneurs to start and run businesses. Furthermore, initiatives such as Make in Turkey have been launched by the Turkish government to encourage foreign investors to set up manufacturing plants in Turkey. In addition, the country is pursuing a bold goal to seek $100 billion in foreign investment by 2023.

These government-sponsored initiatives have a direct impact on your country's ability to start and run a business. Whether it's building permits or tax incentives, you'll need to know what these regulations are and how they effect your industry. The Turkish government has worked hard to improve business-friendly legislation and programmes, making it easier for entrepreneurs to launch new businesses. For foreigners, starting a business in Turkey has never been easier. Many businesses, especially digital businesses such as e-commerce stores and web development firms, qualify for special tax status (reduced taxes). TEPAV, for example, is a marketing and market research assistance programme for enterprises.

 

Turkey Industrial Infrastructure;

Turkey's industrial growth has been rapid, and the country is on its way to becoming one of Europe's major manufacturing centres. The Turkish economy is relatively varied, with practically every industry sector represented. Among the most important industrial sectors are textiles and apparel, food processing, automotive parts, mining, construction materials (e.g., cement), chemicals and petrochemicals (including plastics), metallurgy and metal products (including automobiles), electronics and electrical equipment, home appliances, and furniture. Turkey's infrastructure is well-developed, with modern conveniences. Businesses may easily import and export goods thanks to the country's excellent transportation and communication infrastructure. There are also incentives for new investment in industrial districts, as well as asset protection for existing assets, to keep investors safe.

Another benefit of investing in Turkey is that your foreign company can act as an exporter or importer from/to countries with which Turkey has free trade agreements (FTAs). Turkey's urban and industrial infrastructure includes modern ports, airports, highways, trains, telecommunications networks, schools, and hospitals. The country is densely inhabited, with a population of more than 70 million people. It is one of the most tempting marketplaces for exporters all over the world as a result of these qualities.

 

What are the steps for Starting a Business in Turkey?

To begin, you must first register your business name and legal structure with the EAD (Trade Register Office) or MERSS (Merchant Register Service) (Registry), after which you can apply for an official registration certificate from the EAD. After you've completed these processes, you'll be awarded a trade number for your new business. You can immediately start selling your products and services. There are two types of income taxes: corporate and individual income taxes. Individuals pay personal income tax on their earnings, while corporations pay corporate tax on their profits. Both types of taxes must be paid when starting a business in Turkey.

On their earnings, individuals pay personal income tax. Both types of taxes must be paid when starting a business in Turkey. Taxes in Turkey are calculated based on a number of parameters, including sales volume, profit margin, and so on. As a general rule, if you earn more than 1 million Turkish Liras ($230K) each year, you should hire an accountant and adhere to all government tax regulations.

 

Market Size of Turkey

Since 1951, Turkey's population has increased at a rate of 1.33 percent each year (6.98 million people, according to UN World Population Prospects), and is anticipated to reach 79.5 million by 2050, a 2.4-fold increase from 2000 levels. The country's working-age population, defined as those aged 15 to 64, will grow by more than 5 million people, or 18 percent, between 2010 and 2050. Turkey will have a workforce of about 25 million people by 2020. In addition, life expectancy has climbed steadily in recent decades, reaching 70.8 years for men and 75.7 years for women in 2009.

This trend is expected to continue in the next decades, resulting in increased demand for products and services such as health care, transportation, and leisure activities, among others. With a gross domestic product (GDP) of $947 billion and an annual growth rate of 4.5 percent from 2012 to 2013, Turkey's economy is among the world's top 20. The population is youthful, with more than half of the population under 30 years old, and it is growing: total fertility fell from 5.2 children per woman in 1950–55 to 2.1 children per woman in 2000–05, but it maintains one of the highest fertility rates among OECD countries. With a population of over 75 million people, Turkey is one of Europe's most populous countries.

With 11.4 million square kilometres, it is also one of Europe's largest countries, providing plenty of potential customers for your company! There are a variety of tourist sites in the country, including modern towns and beautiful beaches, as well as historical ruins and natural wonders. For entrepreneurs looking for inspiration, these company ideas for Turkey that have already proven their worth are the best place to start.

 

Industrial Growth

TÜBTAK, Koç Holding, and Sabanc Holding are just a few of the multinational companies that have helped Turkey become a worldwide commercial hub. Turkey is one of the world's fastest-growing economies, according to emsi Bayraktar, President of the Istanbul Chamber of Commerce, with plenty of chances for entrepreneurs. It has a young, well-educated populace and various business potential. It will be easier for you to work with people from different nations if you can converse in numerous languages (both Turkish and English are official). If you're considering starting your own business, keep in mind that we can only build our economy if we have solid, long-term growth. This goal can be achieved by increasing industry.

Turkish entrepreneurs might pursue industrial expansion by forging strategic agreements with other companies using vertical integration as a strategy. At times, it appears that everyone wants a piece of Turkey's growing industrial sector. The government has aided by loosening laws and enacting new legislation, but there are other advantages for those who wish to benefit from Turkey's industrialisation. In order to start a business, you will need financial support. Whether you're starting a new business or taking over an existing one, industrial expansion is essential. Turkey's industrial sector accounts for the majority of the country's economic prosperity. Because of its proximity to Europe and well-developed infrastructure, it has grown into an industrial hub.

 

Scope of Chemical Industry in Turkey

Turkey's chemical industry is rapidly growing, and as Europe's primary chemical export and import partner, Turkey is a vital industrial hub for foreign investment. Chemicals are necessary for modern living and the growth of the chemical industry. The Turkish economy relies heavily on the chemical industry. According to TÜK figures published on January 24, 2001, chemicals account for 7.7% of total exports, with finished items accounting for 15.2 percent and raw materials accounting for 3.8 percent. 4. Chemicals are not one of Turkey's top five export categories, but their value as an export sector is continuously growing. In terms of export value, chemicals were ranked ninth in 2013.

In the 2012-2013 (July-June) fiscal year, chemicals accounted for 2.6 percent of total imports and 2.4 percent of total exports, helping to increase the standard of living, which is a measure of a country's level of industrialization. Pharmaceuticals, synthetic soaps, and detergents are just a few of the businesses that benefit greatly from chemical industry products. Pharmaceuticals, synthetic soaps, and detergents are examples of sectors that require a lot of money, low profits, and foreign investment. Profited from the new economic policies, with large increases in both output and exports.

Turkey's chemical industry is currently a vital component of the industry, with sophisticated technology and a wide range of goods, and it is linked into the supply chain of national industries. Turkey, in particular, has a long history of producing chemicals, including a wide spectrum of basic and intermediate chemicals, as well as petrochemicals. Turkey manufactures petrochemicals, inorganic and organic chemicals, fertilisers, paints, pharmaceuticals, soaps and detergents, synthetic fibres, essential oils, and a variety of other chemicals. The exports of Turkey's chemical industry have also increased. Chemical exports climbed by 7% between 2007 and 2020, reaching a total value of US$8.9 million.

As one of the top five countries supplying chrome ore to global markets, Turkey produces and exports some of the most important chrome compounds and derivatives, such as sodium basic chrome sulphate, chromic acid, and chrome oxide. Because to the size of its reserves, mineral quality, and proximity to consumer markets, Turkey has a competitive advantage in boron compounds (borax dehydrate, borax pentahydrate, boric acid, and sodium perborate).

We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 30 of 78 | Total 776 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 30 77 78   Next »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

Solar Panel

Solar panel refers either to a photovoltaic module, a solar thermal energy panel, or to a set of solar photovoltaic (PV) modules electrically connected and mounted on a supporting structure. A PV module is a packaged, connected assembly of solar cells. Solar panels can be used as a component of a larger photovoltaic system to generate and supply electricity in commercial and residential applications. Each module is rated by its DC output power under standard test conditions (STC), and typically ranges from 100 to 320 watts. The efficiency of a module determines the area of a module given the same rated output - an 8% efficient 230 watt module will have twice the area of a 16% efficient 230 watt module. There are a few solar panels available that are exceeding 19% efficiency. A single solar module can produce only a limited amount of power most installations contain multiple modules. A photovoltaic system typically includes a panel or an array of solar modules, an inverter, and sometimes a battery and/or solar tracker and interconnection wiring. India solar power products market is projected to grow at a CAGR of more than 11% to surpass $ 7.6 billion by 2024 on the back of increasingly stringent policy and regulatory framework and rising environmental concerns. The Ministry of New and Renewable Energy has set a target of 100 GW of solar power generation capacity by 2022. To achieve the target, government has taken several initiatives in the form of offering subsidies, financial assistance, incentives to manufacturers, power producers and even customers. The government has also partnered with several nodal agencies at the central and state levels for the installation of off-grid SPV systems. Subsidies are made available to the customers to encourage installation of grid connected rooftop photovoltaics. Additionally, rising per capita income and developments in the photovoltaic technologies are further anticipated to positively influence India solar power products market during forecast period. Few Indian major players are as under Alectrona Energy Pvt. Ltd Alpex Solar Pvt. Ltd. Bright Solar Ltd. Central Electronics Ltd. Devsun Solar Pvt. Ltd
Plant capacity: Solar Panel:83.3 KW / dayPlant & machinery: 162 lakhs
Working capital: -T.C.I: Cost of Project : Rs 804 lakhs
Return: 28.00%Break even: 54.00%
Add to Inquiry Add to Inquiry Basket

Particle Board from Wheat/Rice Straw

Agricultural waste or residue is made up of organic compounds from organic sources such as rice straw, wheat straw, oil palm empty fruit bunch, sugar cane bagasse, coconut shell, and others. Straw, the stalks of grasses, particularly of such cereal grasses as wheat, oats, rye, barley, and buckwheat.Rice straw and wheat straw are agricultural side products and can be collected after harvest of the main product, paddy rice/rough rice orwheat grain. Rice straw and wheat straw are a lignocellulosic biomass. Relative to other agricultural by-products, it contains a high amount of inorganic components and ash. Rice straw is a low cost biomass. Construction industry is one of the fastest growing sectors in India. Rapid construction activity and growing demand of houses has lead to the short fall of traditional building materials. Bricks, Cement, sand, and wood are now becoming scares materials. Demand of good quality of building materials to replace the traditional materials and the need for cost effective and durable materials for the low cost housing has necessitated the researchers to develop variety of new and innovative building materials. Construction materials of special requirements for the houses in different geographical region to overcome the risk of natural hazard and for protection from sever climatic conditions has also emphasised the need for development of lightweight, insulating, cost effective, durable and environment friendly building materials. The particle board market reached a value of US$ 19.3 Billion in 2018, growing at a CAGR of 6.1% during 2011-2018. Particle boards are mostly used in places such as recording studios and concert venues due to their excellent sound-absorbing properties. These are also used for making household furniture such as kitchen cabinets, bookcases, doors, windows, and covering the walls and floor. Moreover, particle boards can be painted, wallpapered and laminated which adds to the aesthetic quality of the surroundings. Owing to these factors, the market is expected to reach a value of US$ 25 Billion by 2024. Few Indian major players are as under Amazon Wood Pvt. Ltd. Asian Pre-Lam Inds. Pvt. Ltd. Associate Decor Ltd. Bajaj Eco-Tec Products Ltd. Best Board Ltd.
Plant capacity: Particle Board (Size 6x3x0.471'): 5,000,000.0 Sq.Mtrs. / AnnumPlant & machinery: 335 lakhs
Working capital: -T.C.I: Cost of Project : Rs 930 lakhs
Return: 28.00%Break even: 57.00%
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) Amoxicillin Trihydrate, Azithromycin & Paracetamol

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. Azithromycin is used to treat certain bacterial infections, such as bronchitis; pneumonia; sexually transmitted diseases (STD); and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs. Paracetamol is a commonly used medicine that can help treat pain and reduce a high temperature (fever). It is often recommended as one of the first treatments for pain, as it's safe for most people to take and side effects are rare. India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. Huge investment promises from different countries predict a bright future for India. It has a well-developed administration and an independent judicial system with an ever-growing consumer base. It has a huge pool of hard-working skilled workers in all fields. The government has set up tax and non-tax incentives to establish new industrial entities in specific sectors, which include energy, ports, highways, electronics, and software. The Make in India initiative was launched by the government in 2014 and received an excellent response from the developed nations. The government has also created special areas dedicated to export, called export-processing zones (EPZs) or special economic zones (SEZs), to encourage foreign investment. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Patent expirations of blockbuster drugs give rise to generic versions of these molecules, wherein the manufacturers bear the cost. After a patent expires, R&D investments done by the company are no longer beneficial for the company. API production requires a huge capital amount as the process needs extremely systematic protocols. Thus, pharmaceutical companies benefit from outsourcing API production, as it eliminates the need for labor force and installing expensive manufacturing units. Strategic outsourcing allows companies to focus on their core competencies, ultimately resulting in increased productivity. These factors are also projected to drive the active pharmaceutical ingredient market growth. The growth of active pharmaceutical ingredients market is marked by the huge demand for drugs like analgesics, anti-infectives and diabetes, and pain management drugs. But with the rising trend of increasing research and development (R&D) activities, the demand is experiencing a shift towards the advancement of complex APIs that find use in novel formulations, thereby targeting niche therapeutic areas. This facilitates the development of new technologies and ensures a high quality product. Among the problems for pharmaceutical supply chains during this pandemic are the restrictions and impact of COVID-19 on two of the largest global producers of active pharmaceutical ingredients (APIs) and generics: China and India. APIs is a crucial part of the pharma industry’s strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, which also supplies approximately 30 percent of the generic APIs used in the US. However, Indian manufacturers rely heavily on APIs from China for the production of their medicine formulations, procuring around 70 percent from China, the top global producer and exporter of APIs by volume. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd Ankur Drugs & Pharma Ltd. Cian Healthcare Ltd Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Pan Drugs Ltd Piramal Enterprises Ltd.
Plant capacity: Paracetamol : 1,000.0 Kgs / day Azithromycin : 500.0 Kgs / day Amoxicillin Trihydrate: 500.0 Kgs dayPlant & machinery: 175 lakhs
Working capital: -T.C.I: Cost of Project : Rs 1322 lakhs
Return: 29.00%Break even: 47.00%
Add to Inquiry Add to Inquiry Basket

Manufacturing of Active Pharma Ingredients (API) (Amoxicillin Trihydrate, Azithromycin & Paracetamol).

Production of Active Pharma Ingredients (API) (Amoxicillin Trihydrate, Azithromycin & Paracetamol). Investment Opportunities in Pharmaceutical Industry. An active ingredient (AI) is that the ingredient in an exceedingly pharmaceutical drug that's biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active i.e. bulk medicine are utilized in medicine, and therefore the term active substance could also be used for natural products. Thus, depending on the drug’s administered dosage, the reactions and results differ. Certain drugs are comprised of more than one kind of API. Amoxicillin is an antibiotic used to treat variety of bacterial infections. These include middle ear infection, strep throat, pneumonia, skin infections, and tract infections among others. It’s taken orally, or less usually by injection. Active Pharmaceutical Ingredient (API), is that the term used to check with the biologically active component of a drug product (e.g. tablet, capsule). Drug products are typically composed of many elements. The aforementioned API is that the primary ingredient. Alternative ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components utilized in the drug is known as "formulation." Paracetamol is a commonly used medicine that can help treat pain and reduce a high temperature (fever). It is often recommended as one of the first treatments for pain, as it's safe for most people to take and side effects are rare. Azithromycin is an antibiotic used for the treatment of variety of bacterial infections. This includes middle ear infections, strep throat, pneumonia, traveler's diarrhea, and bound alternative intestinal infections it also can be used for variety of sexually transmitted infections, as well as chlamydia and gonorrhea infections. At the side of alternative medications, it's going to even be used for malaria. It may be taken by mouth or intravenously with doses once per day. It is on the world Health Organization's List of Essential Medicines, the safest and most effective medicines required in a very health system. It’s one in all the most usually prescribed antibiotics in children. Trim ox is on the market as a generic medication. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Azithromycin alone and in combination with different medications is currently being studied for the treatment of coronavirus wellness 2019 (COVID-19). Currently, azithromycin has been used with hydroxychloroquine to treat certain patients with COVID-19. However, there are mixed reports of effectiveness once azithromycin was used at the side of alternative medications to treat other viral respiratory infections. Azithromycin also has been used to treat bacterial infections in hospitalized patients with COVID-19. A lot of information is required before any conclusions may be made regarding the possible advantages and risks of using azithromycin either alone or together with hydroxychloroquine in patients with COVID-19. Amoxicillin Trihydrate may be a hydrate that's the Trihydrate type of amoxicillin; a semisynthetic antibiotic, used either alone or together with potassium clavulanate (under the name Augmentin) for treatment of a variety of bacterial infections. It’s a role as an antibacterial drug and an antimicrobial agent. It contains an amoxicillin. Manufacturing Process The manufacturing process of Paracetamol is summarized in the following steps: -charge acetic acid to the reactor. -add p-nitro phenol as a starting material and iron powder as catalyst. -Heat to temp 80-90 ºC. -The reaction is exothermic and temp will rise to 130 ºC. -After slight cooling -Reflux the reaction at 118ºC for 3-4 hours. -Cool to 60 ºC. -Add methanol to the reaction. -Reflux for 1 hour. -distill the methanol and recycle. -Add water to the obtained cake. -And make a solution -Add activated carbon. -Filter -Dry the cake. -Pulverize the dry cake to get the Paracetamol fine powder. Applications:- Communicable Diseases Oncology Diabetes Cardiovascular Diseases Pain Management Respiratory Diseases Other Therapeutic Applications Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Market Outlook Active Pharmaceutical Ingredient Market is valued at USD 172.69 Billion in 2018 and expected to reach USD 263.80 Billion by 2025 with the CAGR of 6.24% over the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Drugs and over-the-counter (OTC) drugs. In 2019, the prescribed drugs segment is expected to account for the most important share of the APIs market. The demand for drugs falling under this class has increased significantly in recent years because of the rising prevalence of target diseases. Additionally, the most important share of the prescription drugs segment also can be attributed to the increased focus of innovator corporations on the development of specialty drugs and affordability of health care. The implementation of significant federal reforms to improve the affordability of healthcare, especially in the, us has expanded the consumption of each traditional and specialty medicine. Also, inflation has played a key role in enhancing revenue from the sales of prescription drugs, significantly specialty drugs. All these factors are collectively responsible for the large share of this phase. Based on the kind of drug, the APIs market can be classified into two segments prescribed. Manufacturer Insights On the basis of type of manufacturer, the API market has been segmented into merchant and captive APIs. Captive API command the most important share in 2019 because of simple availability of raw materials and intensive capitalization of major key players for the development of high-end manufacturing facilities. API is calculable to be the fastest-growing segment over the forecast period. The segment growth is driven by factors similar to high cost of in-house manufacturing of those molecules and rising demand for biopharmaceuticals. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs Active Pharmaceutical Ingredient (APIs) are portions of any drugs that are biologically active in nature. The APIs have significant use in the manufacturing of effective and safe medicines. Depending on the drug’s administered dosage, the reactions and results take issue according to the requirement and use for specific treatment of diseases. Sure medicine are contained of over one kind of API. medicine are chosen primarily for his or her active ingredients to treat variety of chronic and infectious diseases similar to diabetes, cancer, arthritis, bone & joint infections, pneumonia, otitis, streptococcal pharyngitis, cellulites, and tract infections. However, the standard will vary widely from one whole to a different. Medicine are chosen primarily from active ingredients within the liquid or solid form like tablet or alternative throughout. Global Active Pharmaceutical Ingredient Market Dynamics The key issue for growth of worldwide Active Pharmaceutical Ingredient market is that the rise of demand for the new drug discovery for treatment of various chronic and infectious diseases like HIV, cancer, arthritis, bone & joint infections, hepatitis-B, Aids etc. across the world. According to WHO in 2018, the worldwide cancer burden has up to 18.1 million new cases as well as 9.6 million deaths across the world. Because of such rise within the cases of cancer, the new drugs discovery using the Active Pharmaceutical Ingredient has become essential. Recently in line with the American Chemical Society in 2019, there has been 48 new drugs has been approved by the fad U.S. out of that 11 for new cancer treatments with the innovative molecular pharmaceutical ingredients. However, the Active Pharmaceutical Ingredient market is hampered by would like for prime investment with huge capital demand for research and developments. Moreover rising health cautiousness among the people with technological advancement immense investment for launching of recent drugs and biological products, acquisitions, collaborations, and regional growth can provide huge opportunity for Active Pharmaceutical Ingredient market. For instance in 2019, Raquel has been acquired by Merck & Co. for roughly around USD 2.7 billion in cash, for making cancer drug using Active Pharmaceutical Ingredient with the most recent small-molecule-focused. Expansion of Manufacturing Facilities Creating Lucrative Opportunities for Market Growth Majority of specialty API companies are increasing their manufacturing facilities for specialty active pharmaceutical ingredients (API) to take care of or gain market share. Substantial investments within the growth of approved specialty active pharmaceutical ingredients (API) is one in all the most important factors among key players in the specialty active pharmaceutical ingredients (API) market. For instance, in early 2020, Wuxi STA opened oligonucleotide API manufacturing facility in Changzhou, China to cope up with the increasing demand. In 2018, Cordon Pharma expanded operations with new commercial oligonucleotide active pharmaceutical ingredients (API) manufacturing capabilities at its FDA inspected Colorado facility. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. Focus on healthcare to drive the active pharmaceutical ingredients market The spending on healthcare has grown at a rapid pace in recent years and it increased at a CAGR of 6.92% between the years 2003 and 2013. The healthcare spending growth was significantly higher than the population growth rate that grew at a CAGR of 1.22% for the same period. The per capita healthcare spending rose from just under US$ 600 in 2003 to above US$ 1000 in 2013, at an average CAGR of 5.62%. The focus on healthcare spending was observed to be a global phenomenon and this directly benefited the active pharmaceutical ingredients market. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Production of Paracetamol (Acetaminophen), bulk pharmaceutical active ingredient Investment Opportunities in APIs KSMs Drug Intermediates Bulk Drug Industries Manufacturing Business Ideas in Pharmaceutical Industry Key Players Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK). Sun Pharmaceutical Industries Ltd. Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Market Research Report on India Lithium-Ion Battery Market, Growth Rate, Size, Share, Trend, Drivers, Competitive Landscape, Opportunity, Limitations, Technological Landscape, Regulatory Framework, PESTEL Analysis, PORTER’s Analysis, Forecast upto 2027

India Lithium-Ion Battery Market, Growth Rate, Size, Share, Trend, Drivers, Competitive Landscape, Opportunity, Limitations, Technological Landscape, Regulatory Framework, PESTEL Analysis, PORTER’s Analysis, Forecast upto 2027 Market By Type (Lithium Cobalt Oxide, Lithium Manganese Oxide, Lithium Iron Phosphate, and Others), By Components (Cathode, Anode, Electrolytic Solution, and Others), By Application (Consumer Electronics, Industrial, and Automotive), and By Region (North India, South India, West India, and East India) The report titled India Lithium-Ion Battery Market, Growth Rate, Size, Share, Trend, Drivers, Competitive Landscape, Opportunity, Limitations, Technological Landscape, Regulatory Framework, PESTEL Analysis, PORTER’s Analysis, Forecast upto 2027 released by Niir Project Consultancy Services, provides a comprehensive analysis on Indian Lithium Ion Battery Market. The report begins with a brief insight into the scenario of the India Lithium Ion Battery industry giving details about market size, market segmentation, competitive landscape and regional information. The report analyzes the lithium Ion Battery market in profundity by covering data points like industry growth drivers, limitations, opportunity emerging trends coupled with technological landscape of the market and the regulatory framework surrounding the market. The India Lithium Ion Battery market is expected to drive due to technological advancement coupled with the surge in acceptance of EV across the region The India Lithium-Ion Battery market projected to reach USD 7 billion at a significant CAGR of over 28% during the forecasted period of 2020-2027 due to the rise in the adoption of electric vehicles across the region. Additionally, the fueling demand for smart devices, coupled with the other consumer products, is one of the primary factors that is projected to drive the Indian lithium-ion batteries market at a significant growth rate. In addition, the strong need for lithium-ion batteries for automotive purposes is anticipated to drive the market. Furthermore, the stringent government controls relevant to CO2 pollution is pushing the lithium-ion battery sector. Moreover, the growing need for eco-friendly energy storage solutions further expected to propel the market for these energy storage solutions. In addition, the declining price of lithium-ion batteries is estimated to provide opportunities for market growth. Type Overview in the India Lithium Ion Battery Market Based on the Type, the India Lithium Ion Battery market segregated into by Lithium Cobalt Oxide, Lithium Manganese Oxide, Lithium Iron Phosphate, and Others. The Lithium Cobalt Oxide segment is estimated to have a significant growth rate during the forecasted period of 2020-2027 across the region owing to its extensive uses, including in telecommunications, laptops, video cameras, and wearables. In addition, the primary purpose of the Lithium Iron Phosphate battery is in electric vehicle power batteries. However, the Lithium Cobalt Oxide type segment is projected to have a lucrative growth rate over the forecasted period by 2027 due to the high energy density of Lithium Cobalt Oxide batteries. Component Technology Segmental Analysis Based on the component technology, the Indian Lithium Ion Battery market segregated into Cathode, Anode, Electrolytic Solution, and Others. The cathode component segment is estimated to hold the largest share during the forecasted period of 2020-2027 across the region as the cathode commonly used in lithium-ion battery production. The cathode often used for the development of positive electrodes for the battery cells. Additionally, cathodes have high density and superior power output for lithium-ion batteries, which is predicted to boost the Indian market substantially. However, the Electrolytic Solution segment is predicted to have a considerable growth rate over the forecasted period by 2027. This is due to the secure, and long-lasting battery needs a durable electrolyte, which can endure current-voltage and elevated temperatures. The electrolyte has a long shelf life, thus providing high lithium-ion durability, which is projected to fuel the Indian market. Application Segmental Analysis Based on the application, the Indian Lithium Ion Battery market segregated into Consumer Electronics, Industrial, and Automotive. The automotive application is expected to be the fastest growing in the Indian lithium-ion battery market due to its fast recharge capability, and high energy density as lithium-ion batteries are the only viable technologies that are capable of fulfilling OEM specifications for automotive drive range and charging time. In addition, the growing acceptance and recognition of EVs, legislation promoting the use of EVs, and government initiatives, around the nation are the factors expected to drive the development of the lithium-ion battery industry at a substantial growth rate. Regional Overview in the India Lithium Ion Battery Market By geography, the India Lithium Ion Battery market segmented into North India, South India, West India, and East India. South region is projected to lead the market by 2027, owing to the region's propelling consumer electronics industry. India Lithium Ion Battery Market: Competitive Landscape Companies such as Exide Industries, Mahindra & Mahindra Limited, ACME Cleantech Solutions Private Limited, Reliance Industries Limited, NEC India Private Limited, Adani Enterprise Ltd, JSW Group, Denso Corp., Samsung SDI Co. Ltd., Rajamane Telectric Pvt. Ltd, Suzuki Motor Corp., Bharat Heavy Electricals Ltd., and other prominent players are the key players in the India Lithium Ion Battery market. Tags:- #lithiumionbattery #battery #BatteryRecycle #batteries #lithium #LithiumionBatteryIndustry #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #businessstartupindia #feasibilityReport #projectreport #technologyindustry #businessbook #futurebusiness #businessdevelopment #LithiumCobaltOxide #ConsumerElectronics #automotiveindustry #LithiumIronPhosphate #Cathode
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) Amoxicillin Trihydrate, Azithromycin & Paracetamol

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active Pharmaceutical Ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The aforementioned API is the primary ingredient. Other ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components used in the drug is known as "formulation." India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. The country has a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one of the largest recipients of FDI in the world. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Majority of specialty API companies are increasing their manufacturing facilities for specialty active pharmaceutical ingredients (API) to take care of or gain market share. Substantial investments within the growth of approved specialty active pharmaceutical ingredients (API) is one in all the most important factors among key players in the specialty active pharmaceutical ingredients (API) market. For instance, in early 2020, Wuxi STA opened oligonucleotide API manufacturing facility in Changzhou, China to cope up with the increasing demand. In 2018, Cordon Pharma expanded operations with new commercial oligonucleotide active pharmaceutical ingredients (API) manufacturing capabilities at its FDA inspected Colorado facility. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Dr. Reddy'S Laboratories Ltd. Glaxosmithkline Pharmaceuticals Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd.
Plant capacity: Paracetamol:1,000 Kgs / day Azithromycin:500 Kgs / day Amoxicillin Trihydrate:500 Kgs / dayPlant & machinery: Rs 175 lakhs
Working capital: -T.C.I: Cost of Project : Rs 1322 lakhs
Return: 29.00%Break even: 47.00%
Add to Inquiry Add to Inquiry Basket

E-Waste Recycling Plant

Electronic wastes, "e-waste", "e-scrap", or "Waste Electrical and Electronic Equipment" ("WEEE") is a description of surplus, obsolete, broken or discarded electrical or electronic devices. Technically, electronic "waste" is the component which is dumped or disposed or discarded rather than recycled, including residue from reuse and recycling operations. Because loads of surplus electronics are frequently coming led (good, recyclable, and non-recyclable), several public policy advocates apply the term "e-waste" broadly to all surplus electronics. Electronic Waste – or e-waste – is the term used to describe old, end-of-life electronic appliances such as computers, laptops, TVs, DVD players, mobile phones, mp3 players etc. which have been disposed of by their original users. While there is no generally accepted definition of e-waste, in most cases, e-waste comprises of relatively expensive and essentially durable products used for data processing, telecommunications or entertainment in private households and businesses. The rising levels of e-waste generation in India have been a matter of concern in recent years. With more than 100 crore mobile phones in circulation, nearly 25 per cent end up in e-waste annually.“India has surely emerged as the second largest mobile market with 1.03 billion subscribers, but also the fifth largest producer of e-waste in the world, discarding roughly 18.5 lakh metric tonnes of electronic waste each year, with telecom equipment alone accounting for 12 per cent of the e-waste’’. The fastest growing sources of waste and is estimated to be increasing by 16-28 per cent every five years. Within each sector a complex set of heterogeneous secondary wastes is created. Although treatment requirements are complicated, the sources from any one sector possess many common characteristics. However, there exist huge variations in the nature of electronic wastes between sectors, and treatment regimes appropriate for one cannot be readily transferred to another. E-Waste or Electronic Waste broadly describes loosely discarded, surplus, broken, obsolete, electrical and electronic devices. E-Waste is an area of immediate and long-term concern as its unregulated accumulation and recycling can lead to major environmental degradation which will pose a major threat to human health. Revolution of IT, new and innovative technologies and globalization of economy have made new electronic products available and affordable. But on the other hand, it has also led to unrestrained resource consumption and E-Waste generation. Electronic waste (e-waste) typically includes discarded computer monitors, motherboards, mobile phones and chargers, compact discs, headphones, television sets, air conditioners and refrigerators. According to the Global E-Waste Monitor 2017, India generates about 2 million tonnes (MT) of e-waste annually and ranks fifth among e-waste producing countries, after the US, China, Japan and Germany. In 2016-17, India treated only 0.036 MT of its e-waste. About 95 per cent of India’s e-waste is recycled in the informal sector and in a crude manner. Only 20 per cent of global e-waste is recycled. The market in Asia-Pacific has been categorized as China, Japan, India, and the rest of Asia-Pacific. The market in Asia-Pacific is expected to register the highest CAGR of 15.25% during the forecast period. Japan is expected to be a leading country-level market and is expected to register a 12.75% CAGR. India is expected to be the fastest-growing country-level market, expected to register the highest CAGR over the next few years. This is due to the growing population in the region. Also, growing awareness of e-waste recycling and government initiatives are the major factors for the growth of the market. India is emerging as one of the world's major electronic waste generators, posing grave concerns to public health and environment alike.Industry body Assocham, said India’s ‘production’ of e-waste is likely to increase by nearly three times, from the existing 18 lakh metric tons (MT) to 52 lakh MT) per annum by 2020 at a compound annual growth rate (CAGR) of about 30%.The Global Electronic Waste Recycling Market is expected to expand at 13.03% CAGR to reach a market value of 39,498.81 Million in 2024. A mere 1.5% of India's total e-waste gets recycled due to poor infrastructure, legislation and framework which leads to a waste of diminishing natural resources, irreparable damage of environment and health of the people working in industry. Over 95% of e-waste generated is managed by the unorganized sector and scrap dealers in this market, dismantle the disposed products instead of recycling it. Few Indian major players are as under E-ParisaraaPvt Ltd Attero India Pvt Ltd, E-waste Recyclers India, Eco Recycling Limited (ECORECO), Hi-Tech Recycling India Pvt. Ltd., Ultrust Solutions Pvt. Ltd.,
Plant capacity: Aluminium : 3 MT / day Mild Steel: 2 MT / day Shredded PCB: 15.00 MT / dayPlant & machinery: Rs 88 lakhs
Working capital: -T.C.I: Cost of Project: Rs 533 lakhs
Return: 29.00%Break even: 59.00%
Add to Inquiry Add to Inquiry Basket

Market Research Report on India Active Pharmaceutical Ingredient (API)

Market Research Report on India Active Pharmaceutical Ingredient (API) Market, Growth Rate, Covid-19 Impact, Economic Impact, Size, Share, Trend, Drivers, Competitive Landscape, Opportunity, Limitations, Technological Landscape, Regulatory Framework, PESTEL Analysis, PORTER’s Analysis, Forecast upto 2027 Market by Manufacturing Process (Captive Manufacturing, Contract Manufacturing), By Type of Synthesis (Synthetic, Biotech), By API Formulation (Generic API, Innovative API), By Application (Cardiovascular Disease & Hematopoietic System, Central Nervous System, Anti-infectives, Respiratory, Gastrointestinal Disorders, Urology, and Others and By Region (North India, South India, West India, and East India) The India API Market is expected to Drive Owing to the R&D Activities and Surge in the Incidence of Chronic Disease The India API market projected to reach USD 27.49 billion at a significant CAGR of over 10.23% during the forecasted period of 2020-2027. Due to the rising up gradation of technology across India and the growing incidence of hereditary cardiac disease, it is further projected to accelerate the API market at a significant rate across the country. Furthermore, the propelling focus on precision medicine is precited to accelerate the India active pharmaceutical ingredient market. Moreover, the use of drug development techniques focused on Artificial Intelligence further expected to boost the market. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Additionally, strategic outsourcing enables enterprises to rely on their core competencies, contributing to improved efficiency, which is anticipated to fuel India's API market. Furthermore, the rising demand for biosimilars across India is predicted to drive the market at a considerable rate. However, the lack of skilled labor is predicted to challenge the growth of the market. Additionally, the increasing penetration of counterfeit drugs further projected to hinder the Indian market's growth substantially. Manufacturing Process Overview in the India API Market Based on the manufacturing process, the India API market segregated into Captive Manufacturing and Contract Manufacturing. The Captive Manufacturing segment is predicted to hold the largest share during the forecasted period of 2020-2027 across the country. It is attributed to the proper manufacturing and strong capitalization of raw materials, which is estimated to boost the India API market significantly. In addition, manufacturing technologies favor in-house production of innovative products to take advantage of the economic opportunities and avoid the proliferation of technologies, which is further predicted to accelerate the market. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Type of Synthesis Overview in the India API Market Based on the type of synthesis, the India API market is segregated into Synthetic and Biotech. The biotech segment is estimated to have the fastest growth rate during the forecasted period of 2020-2027 owing to the propelling technological advancement in the manufacturing process. Additionally, the increasing demand for the therapeutic and diagnostic solution on Red Biotechnology concepts, recombinant, and DNA sequencing technology is anticipated to boost the market. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs API Formulation Overview in the India API Market Based on the API Formulation, the India API market is categorized into Generic API and Innovative API. The Generic API segment is predicted to hold the largest share over the forecasted period of 2020-2027 across the country. It is attributed to the patent expiry of labeled molecules, which is expected to drive the market at a considerable growth rate. In addition, the decreased in the cost of the generic drug is further projected to fuel the India API market. Related Market Research Report: - India Active Pharmaceutical Ingredient (API) Market However, the Innovative API segment is estimated to have a significant growth rate during the forecasted period by 2027 due to the presence of favorable government regulations in the research and development of drugs. Application Overview in the India API Market Based on the Application, the India API market is classified into Anti-infectives, Cardiovascular and Hematopoietic System, Central nervous system, Respiratory, Gastrointestinal Disorders, Urology, and Others. The Cardiovascular and Hematopoietic System segment is expected to hold significant market share in API market over the forecasted period of 2020-2027 across the country due to the increasing prevalence of cardiovascular diseases coupled with the incidence surge of obesity. In addition, the variation in lifestyle has increased the incidence of obesity is further predicted to drive the segment's market. Projects: - Project Reports & Profiles However, the Central nervous system segment is expected to have a considerable growth rate during the forecasted period by 2027 across the country. It is due to the increasing emphasis on early diagnosis & treatment, which is predicted to fuel the market. Additionally, the growing prevalence of neurological diseases and rising funding for neurological diagnostics is estimated to improve the market significantly. Regional Overview in the India API Market By geography, the India API market segmented into North India, South India, West India, and East India. The West India region is projected to hold the largest share during the forecasted period of 2020-2027 owing to technological advancement. In addition, rapidly evolving healthcare facilities and growing healthcare budgets are further anticipated to propel the India API market. Furthermore, the availability of affordable labor across the region is expected to accelerate the region's market. Books: - BOOKS & DATABASES India API Market: Competitive Landscape Companies such as Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Sun Pharmaceutical Industries Limited, GlaxoSmithKline Pharmaceuticals Ltd, Indoco Remedies Ltd., Piramal Enterprises Ltd., Teva Pharmaceutical & Chemical Industries India Pvt. Ltd., Sri Krishna Pharmaceuticals Limited, Pan Drugs Limited, and Other Prominent Players are the key players in the India API market. Tags #MarketResearchReports #MarketReseach #IndustryTrends #IndustryDemands #ActivePharmaceuticalIngredient #API #pharmaceutical #pharmaceuticalindustry #NPCS #projectconsultancy #businessconsultancy #apimarket #chemicalapimarket #biotechapimarket #highpotencyapi #marketforecast #GlobalMarket #GrowthRate #MarketTrend #marketdrivers #marketopportunity #marketanalysis #PESTELAnalysis #MarketEconomic #MarketSize #MarketShare #MarketGrowthRate #markettrends #MarketImpact #marketDemand #MarketStrategy #Marketinvestment #marketinggrowth
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) (Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol)

The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place. Cefalexin, is an antibiotic that can treat a number of bacterial infections. It kills gram-positive and some gram-negative bacteria by disrupting the growth of the bacterial cell wall. Cefalexin is a beta-lactam antibiotic within the class of first-generation cephalosporins. It works similarly to other agents within this class, including intravenous cefazolin, but can be taken by mouth. Cefalexin can be used in those who have mild or moderate allergies to penicillin. However, it is not recommended in those with severe penicillin allergies. Ampicillin is an antibiotic used to prevent and treat a number of bacterial infections, such as respiratory tract infections, urinary tract infections, meningitis, salmonellosis, and endocarditis. It may also be used to prevent group B streptococcal infection in newborns. It is used by mouth, by injection into a muscle, or intravenously. Like all antibiotics, it is not useful for the treatment of viral infections. Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of action of is not known. Paracetamol is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint. Paracetamol is generally safe at recommended doses. The recommended maximum daily dose for an adult is three to four grams. Higher doses may lead to toxicity, including liver failure. Serious skin rashes may rarely occur. It appears to be safe during pregnancy and when breastfeeding. In those with liver disease, it may still be used, but in lower doses. It is classified as a mild analgesic. It does not have significant anti-inflammatory activity. How it works is not entirely clear. Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug (NSAID) class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be used by mouth or intravenously. It typically begins working within an hour India's reliance on pharma ingredient imports has risen over the past few decades due to the higher cost of domestic production, with the price gap reaching as much as 20%-30%, particularly for energy-intensive fermentation-based ingredients used in anti-infectives. Import dependence is more than 90% for some life-saving drugs, including penicillin and ciprofloxacin. India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. The country has a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one of the largest recipients of FDI in the world. Asia Pacific is expected to be the fastest-growing market over the forecast period. Owing to the availability of affordable labor, major companies in the market are setting up API manufacturing plants in developing countries such as China and India. The global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the market value is projected to reach US$ 258.8 Billion by 2025, exhibiting a CAGR of 5.6% during 2020-2025. The API market is competitive in nature and is becoming increasingly competitive. Consequently, manufacturers are required to enhance products in order to gain advantage over previously marketed products. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. The government also notified a scheme to promote bulk drug parks. For selected parks, financial assistance to the tune of 70 per cent of the project cost of common infrastructure facilities will be provided. In the case of Northeast states and hilly states (Himachal Pradesh, Uttarakhand, Union Territory of Jammu & Kashmir, and Union Territory of Ladakh), financial assistance will be 90 per cent of the project cost. The maximum assistance under the scheme for one bulk Drug Park will be limited to Rs 1,000 crore. The total financial outlay of the scheme is Rs 3,000 crore. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd.
Plant capacity: Paracetamol: 500 Kgs / day Cephalexin: 500 Kgs / day Ampicillin Trihydrate: 500 Kgs / day Ibuprofen: 500 Kgs / dayPlant & machinery: Rs 347 lakhs
Working capital: -T.C.I: Cost of Project: Rs 1656 lakhs
Return: 36.00%Break even: 52.00%
Add to Inquiry Add to Inquiry Basket

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol.

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol. API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. For example, an active ingredient to relieve pain is included in a painkiller. This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. Related Projects:- Active Pharma Ingredients (api) The API form that is used in a formulation is often the most thermodynamically stable crystalline form. As such, the phenomenon of hydrogen bonding in combination with there being many functional groups on the API usually results in the available crystalline form being a hydrate. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumonia, Streptococcus pyogenic, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol is used for the relief of mild to moderate pain. The use of the intravenous form for short-term pain in people in the emergency department is supported by limited evidence. In adults it appears to be useful for migraines, tension headaches, perineal pain after childbirth, and kidney stone pain. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. Market Outlook The production-linked incentive scheme - which accounts for INR0.9 billion of planned outlay - offers an incentive of up to 20% of sales for fermentation based products and up to 10% for chemical synthesis-based products for the next eight to nine years. This should help to bridge the price gap and make domestic production more competitive. The government has also allocated USD0.4 billion under the capex assistance scheme to fund up to 90% of the investment need to build common infrastructure facilities in three bulk drug parks. We believe this will aid the investment decisions of Indian pharma companies, particularly in the current environment where the focus in on conserving cash. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Active pharmaceutical ingredients are an active ingredient of any drug or tablet, which possesses medicinal properties. Some drugs with combined therapy have many active ingredients to treat different disorders. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Higher Growth in the APAC Active Pharmaceutical Ingredients Market Healthcare spending has witnessed continued growth for some time now. Even though the proportion of healthcare spending in the APAC region is comparatively low, the growth rate in this strategic region has outpaced that of mature markets in North America and Europe. Rising healthcare spending has led to quality healthcare becoming accessible along with a higher demand for pharmaceutical products across APAC. The pharmaceuticals consumed here are mostly produced in onshore manufacturing units. Furthermore, contract manufacturing organizations are key outsourcing allies for pharmaceutical companies that supply their wares to North America and Europe. Books:- BOOKS & DATABASES Huge investment promises from different countries predict a bright future for India. It has a well-developed administration and an independent judicial system with an ever-growing consumer base. It has a huge pool of hard-working skilled workers in all fields. The government has set up tax and non-tax incentives to establish new industrial entities in specific sectors, which include energy, ports, highways, electronics, and software. Related Videos:- Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit The global active pharmaceutical ingredients market has been broadly segmented based on manufacturer, APIs, drug, therapeutic, and region. In terms of manufacturer, the global market has been classified into in-house API manufacturing and API contract manufacturing. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Videos:- Manufacturing Business Ideas in Pharmaceutical Industry Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. Related Projects:- Startup Opportunities in Active Pharma Ingredients The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. Market Research Reports:- India Active Pharmaceutical Ingredient (API) The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Market Research:- Market Research Reports Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Related Projects: - Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Related Projects:- Active Pharma Ingredients (api) (cephalexin, Ampicillin Trihydrate, Ibuprofen And Paracetamol) Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Related Projects: - Active Pharma Ingredients (API) Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Projects: - Project Reports & Profiles For More Details, Click Here: - Key players Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd. Sanofi India Ltd. Sri Krishna Pharmaceuticals Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd. Triton Laboratories Ltd. For More Details, Click Here: - https://bit.ly/32McBPb Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 30 of 78 | Total 776 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 30 77 78   Next »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top